Journal of Clinical Oncology names study as most important clinical research advance Wednesday, February 06, 2019 Every year the editors of the New England Journal of Medicine (NEJM) choose twelve of the most meaningful studies that have changed medical practice and patient care. NEJM Notable Articles of 2018 recognizes the significance of the TAYLORx | CCTG MAC12 study (ClinicalTrials.gov identifier: NCT00310180). Download the article here: https://www.nejm.org/nejm-special?query=nejm-social&utm_source=twitter&utm_medium=social&utm_campaign=na18 Other featured research includes: Effect of Aspirin on Disability-free Survival in the Healthy Elderly AR101 Oral Immunotherapy for Peanut Allergy Adjunctive Glucocorticoid Therapy in Patients with Septic Shock Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer The Journal of Clinical Oncology has also named TAILORx as one of the most important clinical research advances of 2018. Landmark advances in molecular diagnostics continue, with the most significant achievement made as a result of the TAILORx breast cancer study. This study demonstrated that as many as 70% of women with hormone receptor–positive, node-negative breast cancer could safely forgo adjuvant chemotherapy based on results from a 21-gene assay. The full article is available here: Research advances 2018 About the trial The Assigning Individualized Options for Treatment Rx (TAILORx) breast cancer trial showed no benefit from chemotherapy for 70% of women with the most common form of breast cancer. The study found that for a group of women with hormone receptor (HR)-positive, HER2 negative, axillary lymph node-negative breast cancer, treatment with chemotherapy and hormone therapy after surgery is not more beneficial than with hormone therapy alone. TAILORx | CCTG MAC12 trial showed no benefit from chemotherapy for women with breast cancer
